

# DRIVING ADVANCEMENTS IN THE TREATMENT OF LUNG CANCER



**Sunday 7 August 2022**  
**13.15–14.15 CEST**

**Hall C8**

**Messe Wien Exhibition & Congress Centre**  
**Vienna, Austria**

## SPEAKERS



**Luis  
Paz-Ares**  
Spain



**Natasha  
Leigh**  
Canada



**Michael  
Boyer**  
Australia

## PROGRAMME

Welcome and introduction to innovative treatments for new targets in lung cancer  
**Luis Paz-Ares**

A step forward: KRAS<sup>G12C</sup> inhibitors in NSCLC today and in the future  
**Natasha Leigh**

Striving for improvement in SCLC: Off-the-shelf T cell engaging therapies targeting DLL3  
**Michael Boyer**

Panel discussion and Q&A  
**All**

**AMGEN®**

**Oncology**

This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

SC-ELMAC-CP-00056  
Amgen Europe GmbH, 6343 Rotkreuz, Switzerland  
Date of preparation: July 2022  
www.amgen.com ©2022 Amgen Inc. All rights reserved.